摘要目的:探讨前列腺癌(PCa)组织中极光激酶B(AURKB)、凋亡抑制蛋白重复序列5(BIRC5)的表达水平与临床病理特征、预后的关系。方法:选取2018年10月至2020年10月在唐都医院收治的152例PCa患者作为研究对象，将患者的癌组织标本纳入PCa组(152例)，将对应的癌旁组织标本纳入癌旁组(152例)。采用免疫组化法检测组织中AURKB、BIRC5的表达情况。比较分析AURKB、BIRC5表达水平与PCa患者临床病理特征的关系；采用多因素Cox回归分析探讨影响PCa患者预后的相关因素。结果:PCa组的AURKB、BIRC5的阳性表达率高于癌旁组(均 P<0.05)；Gleason评分≥7分、淋巴结有转移、TNM分期为Ⅲ～Ⅳ期的PCa患者的AURKB阳性表达率、BIRC5阳性表达率均高于Gleason评分<7分、淋巴结无转移、TNM分期为Ⅰ～Ⅱ期患者(均 P<0.05)；患者连续随访3年，其中73例患者存活，总生存率为68.42%(104/152)。PCa患者的3年总生存率与患者的Gleason评分、淋巴结转移、TNM分期等均有相关性(均 P<0.05)。AURKB、BIRC5阴性患者的3年总生存率高于AURKB、BIRC5阳性患者(均 P<0.05)；多因素Cox回归分析结果显示，Gleason评分≥7分、淋巴结转移、TNM分期Ⅲ～Ⅳ期、AURKB阳性、BIRC5阳性均是PCa患者预后的影响因素(均 P<0.05)。 结论:AURKB和BIRC5在PCa患者癌组织中呈高表达，与PCa患者的临床病理特征、预后密切相关，有望作为辅助评估患者预后生存的潜在标志物。

abstractsObjective:To explore the relationship between auroral kinase B (AURKB) and anti-apoptosis protein repeat 5 (BIRC5) expression levels and clinicopathological features and prognosis in prostate cancer (PCa).Methods:A total of 152 PCa patients admitted to our hospital from October 2018 to October 2020 were selected as the study objects. Cancer tissue specimens were included in PCa group (152 cases), and corresponding paracancer tissue specimens were included in paracancer group (152 cases). AURKB and BIRC5 expression were detected by immunohistochemical method. The relationship between AURKB and BIRC5 expression and clinicopathological features of PCa patients was analyzed. The related factors affecting the prognosis of PCa patients were explored by multivariate Cox regression.Results:The positive expression rates of AURKB and BIRC5 in PCa group were higher than those in paracancer group (all P<0.05). The AURKB positive expression rate and BIRC5 positive expression rate in PCa cases with Gleason score ≥7, lymph node metastasis and TNM stage Ⅲ to Ⅳ were higher than those with Gleason score < 7, no lymph node metastasis and TNM stage Ⅰ to Ⅱ (all P<0.05). The patients were followed up for a duration of 3 years, during which 73 individuals survived, resulting in an overall survival rate of 68.42% (104/152). The 3-year overall survival rate among PCa patients exhibited significant correlations with Gleason score, lymph node metastasis, and TNM stage and so on (all P<0.05). The 3-year overall survival rate of AURKB and BIRC5 negative patients was higher than that of AURKB and BIRC5 positive cases (all P<0.05). Multivariate Cox regression analysis showed that Gleason score≥7, lymph node metastasis, TNM stage Ⅲ to Ⅳ, AURKB positive and BIRC5 positive were the prognostic factors of PCa patients (all P<0.05). Conclusions:The expression levels of AURKB and BIRC5 are significantly upregulated in cancer tissues of PCa patients, exhibiting a close correlation with clinicopathological features and prognosis. These findings suggest that AURKB and BIRC5 hold great potential as prognostic markers for assessing the survival outcomes of PCa patients.